Clinical Profile and Prognostic Significance of Natriuretic Peptide Trajectory Following Hospitalization for Worsening Chronic Heart Failure: Findings from the ASTRONAUT Trial
Population
1351 patients hospitalized for worsening chronic heart failure with ejection fraction ≤40%, elevated B-type…
Design
Cohort
Follow-up
median 11.3 months
Authors
Discussion
Loading...
Member takes
Implication
May inform post-discharge risk stratification in HFrEF beyond baseline values; leaves open whether serial monitoring alters management or outcomes.
Structured PICO
P
Population
1351 patients hospitalized for worsening chronic heart failure (HHF) with ejection fraction (EF) ≤40%, elevated B-type natriuretic peptide ≥400 pg/mL or NT-proBNP ≥1600 pg/mL at admission, and available NT-proBNP measurements at baseline (median 5 days after admission) and 1-month follow-up.
O
Outcome
Co-primary endpoints: all-cause mortality and cardiovascular mortality or HHF within 12 monthscomposite
Early post-discharge NT-proBNP trajectory provides independent prognostic value for cardiovascular mortality or heart failure hospitalization in HFrEF patients, beyond absolute NT-proBNP levels.
Limitations
- post-hoc analysis
Cite This Study
Greene et al. (2015) studied this question.